I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| astrocyte | 7 studies | 48% ± 18% | |
| GABAergic neuron | 3 studies | 28% ± 8% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| astrocyte | 7 studies | 48% ± 18% | |
| GABAergic neuron | 3 studies | 28% ± 8% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 3 studies | 29% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 95% | 21.21 | 2512 / 2642 | 0% | 0.00 | 1 / 705 |
| blood vessel | 73% | 11.96 | 970 / 1335 | 0% | 0 | 0 / 0 |
| lung | 72% | 9.27 | 417 / 578 | 0% | 0 | 0 / 1155 |
| spleen | 67% | 13.70 | 162 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 54% | 21.01 | 506 / 929 | 0% | 0 | 0 / 0 |
| kidney | 49% | 4.01 | 44 / 89 | 0% | 0.00 | 1 / 901 |
| adipose | 46% | 5.31 | 559 / 1204 | 0% | 0 | 0 / 0 |
| thymus | 42% | 3.22 | 275 / 653 | 0% | 0 | 0 / 605 |
| liver | 39% | 3.56 | 88 / 226 | 2% | 0.03 | 7 / 406 |
| adrenal gland | 38% | 2.58 | 98 / 258 | 0% | 0 | 0 / 230 |
| heart | 35% | 2.51 | 303 / 861 | 0% | 0 | 0 / 0 |
| prostate | 32% | 2.93 | 79 / 245 | 0% | 0 | 0 / 502 |
| breast | 31% | 3.27 | 144 / 459 | 0% | 0 | 0 / 1118 |
| stomach | 25% | 1.70 | 91 / 359 | 0% | 0 | 0 / 286 |
| pancreas | 25% | 1.99 | 82 / 328 | 0% | 0 | 0 / 178 |
| intestine | 22% | 1.58 | 213 / 966 | 0% | 0 | 0 / 527 |
| esophagus | 16% | 0.95 | 238 / 1445 | 1% | 0.01 | 1 / 183 |
| uterus | 15% | 1.15 | 26 / 170 | 0% | 0.00 | 1 / 459 |
| bladder | 14% | 1.71 | 3 / 21 | 0% | 0 | 0 / 504 |
| ovary | 12% | 0.89 | 21 / 180 | 0% | 0 | 0 / 430 |
| muscle | 9% | 0.50 | 69 / 803 | 0% | 0 | 0 / 0 |
| skin | 8% | 0.46 | 149 / 1809 | 0% | 0 | 0 / 472 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0010789 | Biological process | meiotic sister chromatid cohesion involved in meiosis I |
| GO_0016321 | Biological process | female meiosis chromosome segregation |
| GO_0007060 | Biological process | male meiosis chromosome segregation |
| GO_0045143 | Biological process | homologous chromosome segregation |
| GO_0051754 | Biological process | meiotic sister chromatid cohesion, centromeric |
| GO_0000776 | Cellular component | kinetochore |
| GO_0000779 | Cellular component | condensed chromosome, centromeric region |
| Gene name | MEIKIN |
| Protein name | Meiotic kinetochore factor Meiosis-specific kinetochore protein |
| Synonyms | |
| Description | FUNCTION: Key regulator of kinetochore function during meiosis I: required both for mono-orientation of kinetochores on sister chromosomes and protection of centromeric cohesin from separase-mediated cleavage. Acts by facilitating kinetochore mono-orientation during meiosis I, when kinetochores on sister chromosomes face the same direction and are thus captured and pulled by spindle fibers from the same pole. Also required to prevent cleavage of cohesin at centromeres during meiosis I, possibly by acting as a regulator of the shugoshin-dependent protection pathway. Acts in collaboration with PLK1: required for PLK1 enrichment to kinetochores. Not required during meiosis II or mitosis. . |
| Accessions | ENST00000439905.5 A0A087WXM9 A0A0J9YXL7 ENST00000616644.2 A0A0G2JND4 ENST00000442687.6 |
